Sheng Changya's attitude made Wei Kang very satisfied.
He thought for a while and ordered: "Then use money to clear the way first, cultivate a few media of your own, and start by gaining the right to speak."
"Don't you know a lot of Internet celebrities? You seem to have good connections in the entertainment industry. You can sponsor some people, both at home and abroad, and let them publish more articles and videos. Be sure to have more language versions."
"As for the theme, the people in Eagle Country waste too much electricity, causing the polar icebergs to melt and the sea level rises. The people in Eagle Country eat seafood and empty the ocean. The people in Eagle Country eat too much steak and ruin the ecology of the Amazon rainforest. The Europeans hunt too much in the Philippines. This has led to the extinction of wild animals, and the rich people in the West have been buying ivory, which has led to the dark trade of elephant poaching."
“Whether it’s a video or an article, it must be well-founded, touching, and thought-provoking. It’s best if the white up owner can have a deep introspection for the best effect.”
"Then work it out and win a few more documentary or video awards. There should be many parallel import awards at home and abroad. Anyway, increase your reputation and buy some hot searches to let the domestic people and overseas people know about it. one time."
"Anyway, we don't speak out about these things, and the other side is always smearing us. It's better for us to jump out and make nonsense ourselves. The other side can't prove it, and can only catch us blind."
"When the two sides confront each other, not only will it become more popular, but it will also be easier for the truth to surface and the truth to be argued to become clearer."
"If it doesn't work, let's muddy the waters at the head office and make everyone think that these claims are nonsense. Then no matter what the other side says, no one will believe it, and it will only attract ridicule. Haha."
"Okay, everything is difficult at the beginning. Let's start with the online media. It should be easier and it is in line with the current publicity craze."
"You can make your own plan for the specific content, and just show me the finished product later."
"I believe that with your marketing capabilities, you will be able to successfully achieve your goals."
Sheng Changya listened and took notes. The expression on his face varied from thoughtful to enlightened, and finally he clapped excitedly.
"Boss, what you said is so good. Listening to your words is better than ten years of studying. I have completely understood your intentions and will not let you down. I will contact those up owners soon and be a I’ll give you a detailed plan and then show you the results.”
Wei Kang said with approval: "Yes, it's really easy to talk to smart people. I'm waiting for your good news."
After Sheng Changya left, he called Zhang Chunming, the person in charge of Feizhou, and chatted for several hours.
Confess all your intentions and appoint the other person as the new person in charge of the charity.
Zhang Chunming was very excited about this appointment. In fact, he had long disliked Western charities.
In addition to being unreasonably scolded at procurement bidding meetings, he also often felt the ill will of these charities in his daily operations.
It's just that the other party has been in business for many years and is all-pervasive. He can't resist it for a while and can only swallow his anger.
Nowadays, Sanqing's medicines are becoming more and more famous, their sales are getting higher and higher, and they are deeply recognized by the Filipino people.
The headquarters also established a separate charity organization in the Philippines for him to take charge of, which undoubtedly has great potential.
"Mr. Wei, thank you for your trust. I will live up to your trust and achieve results as soon as possible."
Zhang Chunming was very excited. He had countless ideas in his mind instantly. As long as he planned carefully, many of them could be developed into good plans.
Wei Kang warned: "Very good, remember who our opponent is, and we must unite all Chinese pharmaceutical companies in the Philippines to cooperate with each other for mutual benefit."
"I remember that several pharmaceutical companies already have their own factories in the Philippines. We can definitely cooperate with them to produce some generic drugs. This should comply with relevant preferential policies, reduce taxes a lot, and also lower the tax burden of some countries. Procurement threshold.”
"The local Chinese also have their own chambers of commerce. You have to build a good relationship with them and be their solid backing."
“In short, what Western charities can do, we can do too.”
Zhang Chunming nodded, patted his chest and agreed.
After hanging up the phone, Wei Kang picked up the water glass on the table and moistened his throat.
Suddenly, a notification popped up on the computer on the table.
It turns out that the antihypertensive drugs and two anti-thrombotic drugs have already submitted phase III clinical trial reports and passed the approval of the Food and Drug Administration, and can be officially launched on the market.
Wei Kang couldn't help but be overjoyed. These three cardiovascular and cerebrovascular disease drugs have excellent efficacy and very few side effects. Compared with competing products of the same type on the market, they have great advantages.
He has high hopes for it, hoping to become Sanqing's leading product in this field.
In particular, anticoagulants are benchmarked against apixaban, so a double-blind experiment with a control group was also conducted during the Phase III clinical trials.
After the experiment, the comparison with competing products is very clear. Not only is it more effective at the same dose, but it also has fewer adverse reactions, and it does not affect the taking of other drugs.
Generally speaking, for long-term medications such as antihypertensive drugs, clinical trials will take longer, and safety considerations are taken very seriously.
Because there are already cheap and safe first-line drugs on the market, if a new product is to be launched, it must have stronger advantages than the existing drugs.
One of the most important advantages of these three drugs from Sanqing is that they have very few adverse reactions and basically no interactions with other drugs, making them safer to take.
Only in this way can it pass the marketing approval of the Food and Drug Administration as quickly as possible.
It took almost a year, which was already a long time compared to the time it took other Sanqing drugs to go on the market.
You should know that most users of cardiovascular and cerebrovascular drugs are middle-aged and elderly people. They usually have several underlying diseases and need to take a lot of drugs. Many elderly people cannot remember the drugs they take every day. There are seven or more drugs they take every day. Eight kinds.
Under such circumstances, tolerance to adverse reactions is an important basis for drug selection.
If a patient cannot tolerate a certain drug because of too many side effects, the options will become smaller.
At the same time, when patients take so many drugs at the same time, drug interactions are likely to lead to unexpected and extremely dangerous results.
Drug interactions are difficult to test in clinical trials because the situation is controllable during the trial phase. However, after it is put on the market, the number of people taking it will increase dramatically, and the out-of-control situation of taking other drugs at the same time is inevitable.
Drug interactions are one of the most common reasons for withdrawing approved drugs.
Even pharmaceutical giants will inevitably stumble in this regard and pay a heavy price.
A few years after Bayer launched a lipid-lowering drug in Eagle Country, a serious side effect in muscle tissue was discovered, leading to its withdrawal.
This lipid-lowering drug, called Byco, is often used in combination with another lipid-lowering drug, gemfibrozil, when used in elderly patients. The interaction between the two drugs can lead to fatal rhabdomyolysis.
Before Bayer officially withdrew the drug, there had been more than 30 deaths caused by rhabdomyolysis in Eagle Country alone.
Drug interactions like this are extremely dangerous because they can significantly alter the effective dose of the drug and how long it remains in the patient's body, leading to unpredictable and dire consequences.
These three drugs of Sanqing were able to pass the fast application channel so smoothly because they received high scores in terms of safety.
Soon, Sanqing officially announced its entry into the field of cardiovascular drugs and announced the launch time of these three drugs.
This news quickly attracted widespread attention from peers.
Currently, there are only three or four well-known companies in the world in cardiovascular disease research, including Merck, AstraZeneca, Pfizer and Novartis.
They all cast defensive glances at Sanqing, becoming wary of the new competitors.
Sanqing's impressive record is enough to prove its strength. Although the market for cardiovascular drugs is very vast, there are many types of drugs and the competition is fierce. After years of fighting, they have long been accustomed to the current division of power.
Now another Tyrannosaurus rex has arrived to snatch food, which is bound to cause a bloody storm in this field.
